Ingevity (NGVT) Cash & Equivalents (2015 - 2026)

Ingevity (NGVT) has 12 years of Cash & Equivalents data on file, last reported at $95.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $95.4 million, up 33.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.4 million (up 33.43% YoY), and the FY2025 annual result was $78.1 million, up 14.85% from the prior year.
• Cash & Equivalents rose to $95.4 million in Q1 2026 per NGVT's latest filing, from $78.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $222.6 million in Q1 2022 and troughed at $68.0 million in Q2 2023.
• A 5-year average of $96.1 million and a median of $83.4 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 73.16% in 2022, then soared 60.36% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $76.7 million in 2022, then gained by 25.03% to $95.9 million in 2023, then retreated by 29.09% to $68.0 million in 2024, then gained by 14.85% to $78.1 million in 2025, then advanced by 22.15% to $95.4 million in 2026.
• Business Quant data shows NGVT's Cash & Equivalents at $95.4 million in Q1 2026, $78.1 million in Q4 2025, and $83.4 million in Q3 2025.